Phase II Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1
Protocol: ECOG – EAY191-N2 SCHEMA – EAY191-N2 Please Note: Below is a list of brief eligibility requirements, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038, to discuss full eligibility requirements. Eligibility: The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191. Patients must have disease that can be […]
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Vs. Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
PROTOCOL: SWOG-S1703 SCHEMA – S1703 Please Note: Below is partial eligibility, please contact GHCI Research Department for full eligibility requirements at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! ELIGIBILITY: Step 1 Registration: Patients must have a diagnosis of hormone receptor positive (ER+ and/or PR+), HER-2 negative, metastatic (M1) breast cancer and must be […]